Swedencare AB (publ) (SECARE.ST)
SEK 48.8
(-2.4%)
SEK 48.8
(-2.4%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.65 Billion SEK | -13.0% |
| 2022 | 1.9 Billion SEK | 164.21% |
| 2021 | 721.53 Million SEK | 303.75% |
| 2020 | 178.7 Million SEK | 4998.66% |
| 2019 | 3.5 Million SEK | -62.29% |
| 2018 | 9.29 Million SEK | -45.33% |
| 2017 | 17 Million SEK | -32.0% |
| 2016 | 25 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.64 Billion SEK | -0.91% |
| 2024 Q3 | 1.53 Billion SEK | -4.04% |
| 2024 Q2 | 1.6 Billion SEK | -2.53% |
| 2023 Q1 | 1.89 Billion SEK | -0.53% |
| 2023 Q4 | 1.65 Billion SEK | -5.95% |
| 2023 FY | 1.65 Billion SEK | -13.0% |
| 2023 Q3 | 1.76 Billion SEK | -4.68% |
| 2023 Q2 | 1.85 Billion SEK | -2.43% |
| 2022 Q1 | 1.59 Billion SEK | 121.62% |
| 2022 Q3 | 2.75 Billion SEK | 70.22% |
| 2022 FY | 1.9 Billion SEK | 164.21% |
| 2022 Q2 | 1.61 Billion SEK | 1.15% |
| 2022 Q4 | 1.9 Billion SEK | -30.76% |
| 2021 Q4 | 721.53 Million SEK | 16.75% |
| 2021 FY | 721.53 Million SEK | 303.75% |
| 2021 Q3 | 618 Million SEK | 168.7% |
| 2021 Q2 | 230 Million SEK | 59.58% |
| 2021 Q1 | 144.12 Million SEK | -19.35% |
| 2020 Q3 | 46.87 Million SEK | 2583.17% |
| 2020 FY | 178.7 Million SEK | 4998.66% |
| 2020 Q2 | 1.74 Million SEK | -9.29% |
| 2020 Q1 | 1.92 Million SEK | -45.05% |
| 2020 Q4 | 178.7 Million SEK | 281.24% |
| 2019 Q3 | 2.38 Million SEK | -64.62% |
| 2019 Q2 | 6.75 Million SEK | -42.36% |
| 2019 FY | 3.5 Million SEK | -62.29% |
| 2019 Q1 | 11.71 Million SEK | 26.01% |
| 2019 Q4 | 3.5 Million SEK | 46.78% |
| 2018 Q4 | 9.29 Million SEK | -28.51% |
| 2018 FY | 9.29 Million SEK | -45.33% |
| 2018 Q3 | 13 Million SEK | -13.33% |
| 2018 Q2 | 15 Million SEK | -11.76% |
| 2018 Q1 | 17 Million SEK | 0.0% |
| 2017 FY | 17 Million SEK | -32.0% |
| 2017 Q2 | 21.23 Million SEK | -8.66% |
| 2017 Q3 | 21 Million SEK | -1.1% |
| 2017 Q4 | 17 Million SEK | -19.05% |
| 2017 Q1 | 23.24 Million SEK | -7.01% |
| 2016 Q1 | 11.3 Million SEK | 0.0% |
| 2016 Q4 | 25 Million SEK | 155.13% |
| 2016 Q3 | 9.79 Million SEK | 14.61% |
| 2016 Q2 | 8.55 Million SEK | -24.36% |
| 2016 FY | 25 Million SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | -18747.727% |
| Enzymatica AB (publ) | 26.1 Million SEK | -6254.059% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -380312.844% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | -8660.828% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -34913.722% |
| Nanexa AB (publ) | 4.03 Million SEK | -41035.913% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | -250.063% |
| Probi AB (publ) | 53.79 Million SEK | -2983.072% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 91.903% |
| Toleranzia AB | 850 Thousand SEK | -195029.412% |
| Vivesto AB | 8.16 Million SEK | -20206.072% |